CYPHERPUNK TECHNOLOGIES INC.
CYPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CYPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYPH
Cypherpunk Technologies Inc. (CYPH) is a clinical-stage biopharmaceutical company developing antibody-based cancer therapies, including lead candidate sirexatamab targeting DKK1 in colorectal cancer, with no approved products or revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for CYPHERPUNK TECHNOLOGIES INC..
Similar companies
Cypherpunk Technologies Inc. (CYPH) is a clinical-stage biopharmaceutical company developing antibody-based cancer therapies, including lead candidate sirexatamab targeting DKK1 in colorectal cancer, with no approved products or revenue to date.
- Lead product candidate sirexatamab targets DKK1 in advanced colorectal cancer, with preclinical program FL-501 also in development [sec_mda · as of 2025-08-14].
- No products approved for sale and no revenue generated from product sales; operations funded through equity and debt financings [sec_mda · as of 2025-08-14].
- Cash and equivalents of $7.6 million as of 2026-06-30, with an accumulated deficit of $499.4 million as of June 30, 2025 [sec_mda · as of 2025-08-14].
- Net income of $39.4 million reported as of 2026-06-30, though the company expects to need additional capital before commercialization [sec_mda · as of 2026-03-16].
What works
- The company has a clear focus on a defined target (DKK1) in a large potential market (advanced CRC), with a lead candidate that has advanced into clinical trials [sec_mda · as of 2025-08-14].
- Management has experience in identifying and developing transformational products, which may support pipeline execution [sec_mda · as of 2025-08-14].
- The company reported positive net income of $39.4 million as of 2026-06-30, indicating a potential improvement in financial position [sec].
What to weigh
- The company has no approved products and has never generated revenue from product sales, with all funding dependent on external capital [sec_mda · as of 2025-08-14].
- Cash reserves are low ($7.6 million as of 2026-06-30) relative to accumulated deficit ($499.4 million as of June 30, 2025), raising going-concern risks [sec_mda · as of 2025-08-14].
- Development timelines and costs are highly uncertain, with no reliable estimate for when, if ever, net cash inflows from product candidates may begin [sec_mda · as of 2026-03-16].
- The company must raise additional capital before commercialization, and failure to do so could halt operations [sec_mda · as of 2026-03-16].
From the filings
Quoted directly from source documents.
No products approved for sale and no revenue from product sales
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 14, 2025
Accumulated deficit of $499.4 million as of June 30, 2025
“we had an accumulated deficit of $499.4 million at June 30, 2025”
SEC MD&A · August 14, 2025
Need to raise additional capital before commercialization
“we will need to raise additional capital prior to the commercialization of sirexatamab or any other product candidate.”
SEC MD&A · March 16, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — No products approved for sale and no revenue from product sales; all funding depends on external capital [sec_mda · as of 2025-08-14].
- Low cash runway — Cash of $7.6M as of 2026-06-30 may be insufficient to fund operations without additional financing [sec].
- Development uncertainty — Cannot reasonably estimate the nature, timing, or costs to complete development of any product candidate [sec_mda · as of 2026-03-16].
- Going concern risk — Accumulated deficit of $499.4M as of June 30, 2025, raises substantial doubt about ability to continue as a going concern [sec_mda · as of 2025-08-14].
What to watch
- Progress of sirexatamab clinical trials and any data readouts [sec_mda · as of 2025-08-14].
- Ability to raise additional capital through equity or debt offerings [sec_mda · as of 2026-03-16].
- Changes in cash position and burn rate in upcoming quarterly filings [sec_mda · as of 2025-08-14].
- Regulatory milestones or feedback for sirexatamab or FL-501 [sec_mda · as of 2025-08-14].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run CYPHERPUNK TECHNOLOGIES INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CYPHERPUNK TECHNOLOGIES INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
51.9 months
D/E 0.03 · 18% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
41
Total value held
$8.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,636,828 | $2.9M |
| blackrock, inc. | 2,342,174 | $1.9M |
| susquehanna international group, llp | 1,217,553 | $963K |
| renaissance technologies llc | 725,120 | $576K |
| geode capital management, llc | 571,068 | $454K |
| arete wealth advisors, llc | 12,488 | $295K |
| vanguard fiduciary trust co | 297,086 | $236K |
| citadel advisors llc | 252,100 | $200K |
| state street corp | 140,113 | $111K |
| jane street group, llc | 118,000 | $94K |
Showing top 10 of 41 institutional holders of CYPHERPUNK TECHNOLOGIES INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 11.7%
- Days to cover
- 3.8
- Shares short
- 8,920,114
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CYPH short interestFrequently asked questions
What is the AI investment thesis for CYPHERPUNK TECHNOLOGIES INC.?
Cypherpunk Technologies Inc. (CYPH) is a clinical-stage biopharmaceutical company developing antibody-based cancer therapies, including lead candidate sirexatamab targeting DKK1 in colorectal cancer, with no approved products or revenue to date.
What is CYPHERPUNK TECHNOLOGIES INC.'s lead drug candidate?
CYPHERPUNK TECHNOLOGIES INC.'s most advanced tracked candidate is fl-501 (Preclinical) for cachexia.
Who is the CEO of CYPHERPUNK TECHNOLOGIES INC.?
Mr. Douglas E. Onsi J.D. is the chief executive officer of CYPHERPUNK TECHNOLOGIES INC. (CYPH).
Where is CYPHERPUNK TECHNOLOGIES INC. headquartered?
CYPHERPUNK TECHNOLOGIES INC. (CYPH) is headquartered in Cambridge, MA, United States.
What therapeutic areas does CYPHERPUNK TECHNOLOGIES INC. focus on?
CYPHERPUNK TECHNOLOGIES INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.